Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?

Journal of Clinical Virology

Volumn 68, Issue , 2015, Pages 61-68

  Buti, Maria ^a,b   Casillas, Rosario ^b   Riveiro Barciela, Mar ^b   Homs, Maria ^a,b   Tabernero, David ^a,b   Salcedo, Maria Teresa ^b   Rodriguez Frias, Francisco ^a,b   Esteban, Rafael ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HBeAg chronic hepatitis B; HBsAg levels; HBsAg loss; Sustained response; TDF discontinuation

Indexed keywords

ALANINE AMINOTRANSFERASE; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B VACCINE; TENOFOVIR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOME ANALYSIS; GENOTYPE; HBEAG NEGATIVE CHRONIC HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RETREATMENT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; BLOOD; DRUG MONITORING; HEPATITIS B, CHRONIC; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT WITHDRAWAL;

AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TENOFOVIR; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84930532327     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.05.002     Document Type: Article

References (34)

1. Liaw Y.F., Brunetto M.R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir. Ther. 2010, 15(Suppl. 3):25-33.
2. Hadziyannis S.J., Papatheodoridis G.V. Hepatitis B. e antigen-negative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006, 26:130-141.
3. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012, 57:167-185.
4. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
5. Gara N., Zhao X., Collins M.T., Chong W.H., Kleiner D.E., Jake Liang T., et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol. Ther. 2012, 35:1317-1325.
6. Omata M., Lesmana L.A., Tateishi R., Chen P.J., Lin S.M., Yoshida H., et al. Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 2010, 4:439-474.
7. Hadziyannis S.J., Sevastianos V., Rapti I., Vassilopoulos D., Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012, 143:629-636. e1.
8. He D., Guo S., Chen W., Chen X., Yan G., Wang J., et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect. Dis. 2013, 13:458.
9. Shouval D., Lai C.L., Chang T.T., Cheinquer H., Martin P., Carosi G., et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J. Hepatol. 2009, 50:289-295.
10. Petersen J.H.R., Mauss S., Schlaak J., Schiffelholz W., Eisenbach C., Hartmann H., Wiese M., Boeker K., Loehr H.F., John C., Leuschner M., Trautwein C., Felten G., Trein A., Krause W., Ruppert R., Warger T., Hüppe D. GEMINIS. Effectiveness of Tenofovir for chronic hepatitis B in field practive- 2 year interim results from the prospective german multicenter non-interventional study (GEMINIS). J. Hepatol. 2013, 58:S313.
11. Chen C.H., Lu S.N., Hung C.H., Wang J.H., Hu T.H., Changchien C.S., et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J. Hepatol. 2014, 61:515-522.
12. Ridruejo E., Marciano S., Galdame O., Reggiardo M.V., Munoz A.E., Adrover R., et al. Relapse rates in chronic hepatitis B naive patients after discontinuation of antiviral therapy with entecavir. J. Viral Hepat. 2014, 21:590-596.
13. Patwardhan V.R., Sengupta N., Bonder A., Lau D., Afdhal N.H. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol. Ther. 2014, 40:804-8
14. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008, 359:2442-2455.
15. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
16. Ghany M., Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
17. Gregori J., Salicru M., Domingo E., Sanchez A., Esteban J.I., Rodriguez-Frias F., et al. Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics 2014, (January 21). [Epub ahead of print].
18. Ramirez C., Gregori J., Buti M., Tabernero D., Camos S., Casillas R., et al. A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antivir. Res. 2013, 98:273-283.
19. Chang M.L., Liaw Y.F. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J. Hepatol. 2014, 61:1407-1417.
20. Schirmbeck R., Bohm W., Fissolo N., Melber K., Reimann J. Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen. Eur. J. Immunol. 2003, 33:2429-2438.
21. Nayersina R., Fowler P., Guilhot S., Missale G., Cerny A., Schlicht H.J., et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993, 150:4659-4671.
22. Honorati M.C., Dolzani P., Mariani E., Piacentini A., Lisignoli G., Ferrari C., et al. Epitope specificity of Th0/Th2CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997, 112:2017-2027.
23. Gerlich W.H., Glebe D., Schuttler C.G. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J. Viral Hepat. 2007, 14(Suppl. 1):16-21.
24. Chan H.L., Wang H., Niu J., Chim A.M., Sung J.J. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir. Ther. 2007, 12:345-353.
25. Jeng W.J., Sheen I.S., Chen Y.C., Hsu C.W., Chien R.N., Chu C.M., et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013, 58:1888-1896.
26. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 1999, 180:15-26.
27. Pol S., Nalpas B., Driss F., Michel M.L., Tiollais P., Denis J., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 2001, 34:917-921.
28. Fontaine H., Kahi S., Chazallon C., Bourgine M., Varaut A., Buffet C., et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial-ANRS HB02 VAC-ADN. Gut 2015, 64:139-147.
29. Cai W., Xie Q., An B., Wang H., Zhou X., Zhao G., et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J. Clin. Virol. 2010, 48:22-26.
30. Liang Y., Jiang J., Su M., Liu Z., Guo W., Huang X., et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol. Ther. 2011, 34:344-352.
31. Schildgen O., Schewe C.K., Vogel M., Daumer M., Kaiser R., Weitner L., et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004, 18:2325-2327.
32. Osiowy C., Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J. Clin. Microbiol. 2003, 41:5473-5477.
33. Wirth S., Bortolotti F., Brunert C., Postberg J., Hensel K., Jenke A. Hepatitis B. virus genotype change in children is closely related to HBeAg/anti-HBe seroconversion. J. Pediatr. Gastroenterol. Nutr. 2013, 57:363-366.
34. Jardi R., Rodriguez-Frias F., Schaper M., Giggi E., Tabernero D., Homs M., et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: influence of antiviral therapy. J. Hepatol. 2008, 49:695-701.